Login to Your Account



Worth More Dead Than Alive?

Orexigen Mulls Next Steps After FDA's Contrave Surprise

By Tom Wall


Wednesday, February 2, 2011
"Premature to speculate" and "need more details" were default answers for Orexigen Therapeutics Inc. CEO Michael Narachi as he attempted to respond to questions during a conference call Tuesday about what's next for the San Diego-based company's new drug application (NDA) for Contrave (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription